Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance

BACKGROUND: Dimethyl fumarate (DMF), a disease-modifying therapy for multiple sclerosis (MS), causes lymphopenia in a fraction of patients. The clinical significance of this is unknown. Several cases of progressive multifocal leukoencephalopathy in lymphopenic fumarate-treated patients have raised c...

Descripción completa

Detalles Bibliográficos
Autores principales: Longbrake, Erin E, Naismith, Robert T, Parks, Becky J, Wu, Gregory F, Cross, Anne H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4636217/
https://www.ncbi.nlm.nih.gov/pubmed/26550483
http://dx.doi.org/10.1177/2055217315596994

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4636217/
https://www.ncbi.nlm.nih.gov/pubmed/26550483
http://dx.doi.org/10.1177/2055217315596994

Ejemplares similares